TrialPathogens (Basel, Switzerland)2025

Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant.

Pierre Malchair et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.